What's At Stake: Biopharma Profit Growth Reliant On Price Increases
Price increases generated 100% of net US earnings growth at major biopharma firms in 2016, according to investment analyst report assessing threat of continued pricing pressure.
You may also be interested in...
List Price Increase 'Incentives' Must Be Reversed, HHS Nominee Azar Says
Senate Finance Committee Democrats grill HHS Secretary nominee Alex Azar about his ability to foster solutions to high drug pricing given his industry background, as well as his support for alternative financing in Medicaid.
Express Scripts-Anthem Split Could Signal Positive Trend For Biopharma
Express Scripts is losing its biggest customer, which could be a sign that plan sponsors are looking for more control over their pharmacy spending -- bad news for the big PBMs but good news for biopharma?
Drugs' Net Price Only Growing Modestly, Express Scripts Finds
Overall unit cost in commercial insurance market was up only 2.5% in 2016 despite 11% list increase for brands, PBM's Drug Trend Report concludes; findings could be counterpoint to public and policymaker concerns with drug pricing.